You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 5,948,438

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,948,438

Title:	Pharmaceutical formulations having improved disintegration and/or absorptivity
Abstract:	An oral solid dosage form, comprising a compressed tablet including an excipient comprising (a) microcrystalline cellulose; and (b) a compressibility augmenting agent which (I) physically restricts the proximity of the interface between adjacent cellulose surfaces (e.g., silicon dioxide); or (ii) inhibits interactions between adjacent cellulose surfaces (e.g., sodium lauryl sulfate); or (iii) accomplishes both (i) and (ii) above; together with an active agent, is disclosed which provides improved disintegration and/or absorptivity to the oral solid dosage form when orally administered to human patients. The excipient comprises agglomerated particles of said microcrystalline cellulose and said compressibility augmenting agent in intimate association with each other.
Inventor(s):	Staniforth; John N. (Bath, GB), Sherwood; Bob E. (Amenia, NY), Hunter; Edward A. (Glenham, NY)
Assignee:	Edward Mendell Co., Inc. (Patterson, NY)
Application Number:	08/868,744
Patent Claims:	1. An oral solid dosage form, comprising a compressed tablet including an excipient comprising (a) microcrystalline cellulose; and (b) a compressibility augmenting agent which (i) physically restricts the proximity of the interface between adjacent cellulose surfaces; or (ii) inhibits interactions between adjacent cellulose surfaces; or (iii) accomplishes both (i) and (ii) above; said composition comprising agglomerated particles of said microcrystalline cellulose and said compressibility augmenting agent in intimate association with each other; and a therapeutically active agent. 2. The composition of claim 1, wherein said compressibility augmenting agent provides a hydrophobic boundary at cellulose surfaces, and improves absorptivity of the therapeutically active agent. 3. The composition of claim 1, wherein said compressibility augmenting agent (i) is a silicon dioxide having an average primary particle size from about 1 nm to about 100 .mu.m, and improves disintegration of the dosage form. 4. The composition of claim 1, wherein said compressibility augmenting agent (i) is colloidal silicon dioxide. 5. The composition of claim 1, wherein said compressibility augmenting agent (ii) is a surfactant having an HLB value of at least 10. 6. The composition of claim 1, wherein said compressibility augmenting agent (ii) is a surfactant having an HLB value from about 15 to about 50. 7. The composition of claim 1, wherein said compressibility augmenting agent (ii) is sodium lauryl sulfate. 8. The composition of claim 1, wherein said compressibility augmenting agent (ii) is polysorbate 40.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.